United States: Humira Patents Invalidated In Inter Partes Reviews

Last Updated: June 23 2017
Article by Christopher Betti and Jennifer Dienes

AbbVie's arguments raised in a prior IPR were key to the PTAB's finding of no commercial success.

The Patent Trial and Appeal Board (PTAB) found all of the claims of three AbbVie Biotechnology Ltd. (AbbVie) patents directed to Humira unpatentable in the last month as a result of three inter partes reviews (IPRs) requested by Coherus Biosciences Inc. (Coherus). On May 16, 2017 the PTAB issued a Final Written Decision finding all of the claims (1–5) of US Patent No. 8,889,135 (the '135 Patent) unpatentable. Subsequently, the PTAB issued two Final Written Decisions on June 9, 2017 finding claims 1–4 of US Patent No. 9,017,680 (the '680 Patent) and claims 1 and 2 of US Patent No. 9,073,987 (the '987 Patent) unpatentable.

The PTAB rejected all of AbbVie's secondary considerations of nonobviousness, including commercial success; long-felt, unmet need; and unexpected results. Notably, the PTAB rejected AbbVie's assertion that the commercial success of Humira supported the nonobviousness of the claimed invention in part because of statements made by AbbVie in other IPRs challenging patents in the Humira portfolio.1 Here the PTAB found that AbbVie previously relied on features other than those recited in the '135, '680, and '987 Patents as driving Humira's commercial success.

US Patent No. 8,889,135

The '135 Patent, "Methods of Administering Anti-TNFα Antibodies," issued on November 18, 2014, and is directed to methods of treating rheumatoid arthritis with human anti-tumor necrosis factor α (TNFα) antibody. In particular, the patent claims methods involving subcutaneously administering an anti-TNFα antibody with the same six complementarity-determining regions (CDRs) and heavy chain constant region as D2E7 (i.e., Humira) at a dose of 40 mg once every 13–15 days.

Background

On November 9, 2015 Coherus filed an IPR petition for the '135 Patent, which the PTAB instituted on May 17, 2016, to determine whether all of the patent's claims, 1–5, were obvious in view of two references: Kempeni and van de Putte. The PTAB's Final Written Decision issued just a day short of one year after institution.

In its petition Coherus argued that Kempeni and van de Putte rendered claims 1–5 of the '135 Patent obvious.2 Briefly, Coherus argued that Kempeni disclosed that Humira that is intravenously administered biweekly including at a dose of 40 mg has an estimated half-life of 11.6 to 13.7 days. Further, Coherus argued that van de Putte disclosed administering Humira subcutaneously. Thus, Coherus argued that the combination of both references taught each and every element of the claimed invention. Ultimately, the PTAB agreed with Coherus and found that a person of ordinary skill in the art would have been motivated to combine Kempeni and van de Putte to achieve subcutaneous administration of Humira at a dose of 40 mg because such administration would be more desirable for patients (i.e., less expensive and more convenient). AbbVie, on the other hand, argued that a person of ordinary skill in the art would not have been motivated to develop a 40 mg, subcutaneous, every-other-week dosage regimen to treat rheumatoid arthritis, and would not have had a reasonable expectation of success in treating rheumatoid arthritis using such a dosing regimen in view of the prior art's teachings.3

PTAB's Analysis

The PTAB found that Kempeni teaches that D2E7 is safe and effective as a monotherapy when administered subcutaneously or intravenously by single or multiple injections.4 Further, the PTAB found that van de Putte teaches that doses of D2E7 were superior to a placebo and that 20, 40, and 80 mg/week dosages were almost equally efficacious when administered subcutaneously to patients with rheumatoid arthritis.5 Based on these references' disclosures, the PTAB found that together Kempeni and van de Putte disclose or suggest each element of claims 1–5.6

The PTAB characterized the parties' disputes regarding motivation to combine and reasonable expectation of success as "hotly" contested.7 Ultimately, the PTAB sided with Coherus and found that a person of ordinary skill in the art would have had a reason to select a subcutaneous administration route and fixed dosing regimen with a reasonable expectation of success.8

With respect to biweekly administration of a 40 mg dose, the PTAB was not persuaded by Coherus's argument that a person of ordinary skill in the art would have done so based on the disclosed half-life of D2E7.9 In particular, the PTAB noted that Coherus never provided evidence of a drug with a dosing interval that corresponded to its half-life or other evidence showing that persons of ordinary skill in the art routinely use half-lives to create dosing schedules, and AbbVie provided evidence to the contrary.10 However, the PTAB found persuasive Coherus's argument that the disclosure of administration of 0.5 mg/kg of D2E7 biweekly, which is equivalent to a 40 mg subcutaneous dose, would provide a motivation to combine with a reasonable expectation of success.11 Specifically, the PTAB found that "Kempeni expressly discloses a dose that is equivalent to the recited subcutaneous 40 mg dose" and also teaches biweekly administration.12

Additionally, the PTAB found that the record showed that a person of ordinary skill in the art either would have used a clinical approach to design a dosing regimen involving testing different doses and dosing intervals, which AbbVie did for D2E7, or would have used a theoretical model approach.13 AbbVie's expert admitted that the publicly available pharmacokinetic information in June 2001 would not have allowed a pharmacokinetic/pharmacodynamic correlation for modeling purposes because it did not include patient-specific data.14 Nonetheless, he performed a modeling exercise, to which the PTAB afforded little weight, in part because the minimum effective dose of D2E7 was undefined in June 2001.15

Further, the PTAB found that the potential to develop anti-drug antibodies would not have discouraged a person of ordinary skill in the art from pursuing the claimed 40 mg biweekly dosing regimen.16 Specifically, Kempeni discloses that one would expect the fully human D2E7 to be less immunogenic than other antibodies that contain nonhuman portions.17 Moreover, the PTAB did not find sufficient evidence to show that fluctuations in the minimum and maximum steady state plasma concentrations for a 40 mg biweekly treatment would have raised sufficient safety issues to discourage use of such a dosing regimen.18

AbbVie further argued that there was evidence of a long-felt, unmet need; unexpected results; and commercial success supporting a finding of nonobviousness.19 In particular, AbbVie heavily relied on Humira's dosing regimen as driving its commercial success. In response, Coherus pointed to AbbVie's argument in a related IPR that the commercial success of Humira

was driven in large part by (i) the ability of patients to self-administer a liquid antibody formulation via single dose subcutaneous administration . . . without lyophilization and the accompanying need for reconstitution, and (ii) the fact that it is stable enough to be commercially viable (e.g., to withstand shipping and storage for periods of time typical or biologic therapies).20

AbbVie failed to mention that the dosing regimen was responsible for the commercial success of Humira. As such, the PTAB found that it was not clear whether the sales of Humira were due to the claimed dosing regimen or the formulation that AbbVie argued was the driver of commercial success in the related IPR. Consequently, the PTAB was not persuaded by AbbVie's evidence of commercial success.21

Similarly, the PTAB was not persuaded that the claimed dosing regimen satisfied a long-felt, unmet need.22 The PTAB concluded that the prior art disclosed biweekly dosing regimens and subcutaneous dosing of anti-TNFα agents.23 Further, the PTAB found that AbbVie failed to tie its supporting evidence to the claimed 40 mg dose24 and failed to sufficiently connect its success, in view of others' failures, to a biweekly subcutaneous dose.25 Instead, the PTAB concluded that the "driving force behind the satisfaction of a long-felt need and success where others had failed was the introduction of the first fully human anti-TNFα antibody, not the claimed dosing regimen."26 Likewise, the PTAB rejected AbbVie's arguments regarding unexpected results.27 According to the PTAB, AbbVie merely reiterated its teaching-away arguments, which were found unpersuasive for the reasons discussed above.28

In view of the foregoing, the PTAB concluded that Coherus demonstrated by a preponderance of the evidence that claims 1–5 of the '135 Patent were obvious over the combination of Kempeni and van de Putte.29

US Patent No. 9,017,680 and US Patent No. 9,073,987

The '680 Patent, "Methods of Administering Anti-TNFα Antibodies," issued on April 28, 2015, and, like the '135 Patent, is directed to methods of treating rheumatoid arthritis with human anti-TNFα antibody (i.e., a method involving administering 40 mg of anti-TNFα antibody once every 13–15 days with methotrexate where the anti-TNFα antibody has the same six CDRs and heavy chain constant regions as D2E7); and the '987 Patent, "Methods of Administering Anti-TNFα Antibodies," issued on July 7, 2015, and is directed to methods of treating rheumatoid arthritis by subcutaneously administering a 40 mg dose of human anti-TNFα antibody once every 13–15 days (where the anti-TNFα antibody has specific CDRs, variable light chain regions, and variable heavy chain regions).

Background

On December 7, 2015, Coherus filed IPR petitions for the '680 Patent and the '987 Patent. Both were instituted on June 13, 2016. The '680 Patent IPR was instituted to determine whether all of the patent's claims, 1–4, were obvious in view of Kempeni and van de Putte, and the '987 Patent IPR was instituted to determine whether all of the patent's claims, 1–2, were obvious in view of the same references, which were also the same references asserted against the '135 Patent.

In its petitions, Coherus argued that van de Putte and Kempeni rendered claims 1–4 of the '680 Patent and claims 1–2 of the '987 Patent obvious.30 As with the '135 Patent's IPR, AbbVie argued that a person of ordinary skill in the art would not have been motivated to develop a 40 mg, subcutaneous, every-other-week dosing regimen to treat rheumatoid arthritis, and would have no reasonable expectation of success in doing so.31

PTAB's Analysis

The PTAB made the same findings regarding Kempeni's and van de Putte's disclosures as discussed above with respect to the '135 Patent's IPR.32 For similar reasons, the PTAB concluded that Kempeni and van de Putte together disclose every element of claims 1–4 of the '680 Patent and claims 1–2 of the '987 Patent.33

Similar to the '135 Patent's IPR, Coherus argued that a person of ordinary skill in the art would have been led to administer 40 mg of D2E7 subcutaneously every 13–15 days in combination with methotrexate, as claimed in the '680 Patent, and would have expected it to be safe and effective in treating rheumatoid arthritis.34 The parties' arguments largely mirrored those in the '987 Patent IPR.35

In view of the foregoing, the PTAB concluded that Coherus demonstrated by a preponderance of the evidence that claims 1–4 of the '680 Patent and claims 1–2 of the '987 Patent were obvious over the combination of Kempeni and van de Putte.36

Footnotes

1 See IPR2016-01018 regarding US Patent No. 9,114,166.

2 Final Written Decision at p. 10.

3 Id.

4 Id. at p. 12.

5 Id. at p. 13.

6 Id. at pp. 14-15.

7 Id. at p. 16.

8 Id. at pp. 16-17.

9 Id. at p. 18.

10 Id. at p. 22.

11 Id. at pp. 18, 24.

12 Id. at p. 25.

13 Id. at p. 33.

14 Id.

15 Id.

16 Id.

17 Id. at pp. 33-34.

18 Id. at p. 35.

19 Id. at p. 38.

20 Id. at pp. 39-40.

21 Id.

22 Id. at pp. 42-43.

23 Id. at p. 42.

24 Id.

25 Id.

26 Id.

27 Id. at p. 43.

28 Id.

29 Id. at p. 44.

30 '680 Patent Final Written Decision at p. 10; '987 Patent Final Written Decision at p. 9.

31 Id.

32 Id. at pp. 10-14.

33 Id. at p. 15.

34 Id. at p. 16.

35 Id. at pp. 16-17.

36 '680 Patent Final Written Decision at p. 44; '987 Patent Final Written Decision of p. 42.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions